Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2016 December;58(4) > Minerva Oftalmologica 2016 December;58(4):65-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

ORIGINAL ARTICLES   Freefree

Minerva Oftalmologica 2016 December;58(4):65-9

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Evaluation of the efficacy of a new escin-based, multi-component formulation in reducing eyelid edema

Gianni BELCARO 1, Mark DUGALL 1, Giada MARAMALDI 2, Stefano TOGNI 2, Luca GIACOMELLI 3

1 Department of SMO Biotech, Irvine3 Labs, Circulation Sciences, University of Chieti-Pescara, Chieti, Italy; 2 Indena SpA, Milan, Italy; 3 Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, University of Genoa, Genoa, Italy


PDF


BACKGROUND: The aim of this study was to evaluate the synergistic effect of different active ingredients with well-known anti-inflammatory activity and ability to stimulate skin microcirculation in attenuating the eyelid edema.
METHODS: In this randomized, vehicle-controlled study, 57 healthy subjects with lower eyelid bags were advised to apply in the periorbital region and surrounding area, 1 g of the assigned formulation twice a day for 8 weeks. The three topical products used in this study were: vehicle (no active ingredients); escin 0.2% cream; a multi-component cream (Phytosome®) composed by escin β-sitosterol, Zanthoxylum bungeanum fruit extract, ethyl ximenynate and ruscogenins. Each individual was subjected to several non-invasive examinations (elastosonography, laser Doppler flowmetry, thermography, transcutaneous tension of oxygen test, infra-orbital 3D reconstruction) at the following time period: at inclusion, to evaluate the basal conditions of the subject prior to the beginning of the study, after 4 weeks and 8 weeks to evaluate the efficacy of the formulation tested.
RESULTS: The 57 individuals recruited in this study were randomly assigned to either vehicle group (N.=18), escin 0.2% cream group (N.=19) or multi-component cream group (N.=20). The escin-based multi-component cream showed beneficial effects in all the microcirculatory parameters of the lower eyelid area evaluated at 4 and 8 weeks. Moreover, the multi-component formulation resulted also to be effective in reducing lower eyelid puffiness at 4 weeks, with respect to the condition at inclusion.
CONCLUSIONS: Our pilot study showed the efficacy of an escin-based, multi-component cream in improving under-eyes skin microcirculation and reducing the eyelid edema, suggesting a potential beneficial role in alleviating post-operative eyelid edema.

top of page